CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
CytoSorbents (NASDAQ: CTSO) has launched a newly redesigned and consolidated website at www.cytosorbents.com. The website, themed 'Working to Save Lives Together', showcases two decades of collaboration with the medical and research communities to refine therapies like CytoSorb®, ECOS-300CY®, and VetResQ®. The new site features a modern design, intuitive navigation, and comprehensive information for healthcare professionals and investors.
Key features include a user-friendly layout, enhanced content, news updates, a searchable resource library with over 1,000 peer-reviewed publications, and a dedicated investor relations section. The website aims to provide a unified online presence for the company's corporate and product information, highlighting its commitment to blood purification technology and life-saving therapies.
CytoSorbents (NASDAQ: CTSO) ha lanciato un sito web recentemente ridisegnato e consolidato all'indirizzo www.cytosorbents.com. Il sito, caratterizzato dal tema 'Lavoriamo Insieme per Salvare Vite', mette in luce due decenni di collaborazione con le comunità mediche e di ricerca per perfezionare terapie come CytoSorb®, ECOS-300CY® e VetResQ®. Il nuovo sito presenta un design moderno, una navigazione intuitiva e informazioni complete per professionisti della salute e investitori.
Le caratteristiche principali includono un layout user-friendly, contenuti migliorati, aggiornamenti di notizie, una libreria di risorse ricercabile con oltre 1.000 pubblicazioni revisionate da esperti, e una sezione dedicata alle relazioni con gli investitori. Il sito web mira a fornire una presenza online unificata per le informazioni aziendali e sui prodotti, evidenziando il suo impegno verso la tecnologia di purificazione del sangue e le terapie salvavita.
CytoSorbents (NASDAQ: CTSO) ha lanzado un sitio web recientemente rediseñado y consolidado en www.cytosorbents.com. El sitio, con el tema 'Trabajando Juntos para Salvar Vidas', destaca dos décadas de colaboración con las comunidades médicas y de investigación para perfeccionar terapias como CytoSorb®, ECOS-300CY® y VetResQ®. El nuevo sitio presenta un diseño moderno, navegación intuitiva e información completa para profesionales de la salud e inversores.
Las características clave incluyen un diseño fácil de usar, contenido mejorado, actualizaciones de noticias, una biblioteca de recursos que se puede buscar con más de 1,000 publicaciones revisadas por pares, y una sección dedicada a las relaciones con los inversores. El sitio web tiene como objetivo proporcionar una presencia en línea unificada para la información corporativa y de productos de la empresa, destacando su compromiso con la tecnología de purificación de sangre y terapias que salvan vidas.
CytoSorbents (NASDAQ: CTSO)는 www.cytosorbents.com에서 새롭게 디자인되고 통합된 웹사이트를 출시했습니다. '생명을 구하기 위해 함께 작업하기'라는 주제로 구성된 이 웹사이트는 CytoSorb®, ECOS-300CY®, VetResQ®와 같은 치료법을 개선하기 위해 의료 및 연구 커뮤니티와 20년 동안 협력한 내용을 보여줍니다. 새 사이트는 현대적인 디자인, 직관적인 탐색 및 의료 전문가 및 투자자를 위한 포괄적인 정보를 제공합니다.
주요 특징으로는 사용자 친화적인 레이아웃, 향상된 콘텐츠, 뉴스 업데이트, 1,000개 이상의 동료 검토된 출처가 포함된 검색 가능한 자원 라이브러리, 그리고 투자자 관계에 대한 전용 섹션이 포함됩니다. 이 웹사이트는 회사의 기업 및 제품 정보를 통합된 온라인으로 제공하는 것을 목표로 하며, 혈액 정화 기술과 생명을 구하는 치료에 대한 약속을 강조합니다.
CytoSorbents (NASDAQ: CTSO) a lancé un site Web récemment redésigné et consolidé à l'adresse www.cytosorbents.com. Le site, sous le thème 'Travaillons Ensemble pour Sauver des Vies', met en avant deux décennies de collaboration avec les communautés médicales et de recherche pour perfectionner des thérapies telles que CytoSorb®, ECOS-300CY® et VetResQ®. Le nouveau site présente un design moderne, une navigation intuitive et des informations complètes pour les professionnels de la santé et les investisseurs.
Les caractéristiques clés comprennent une mise en page conviviale, un contenu amélioré, des mises à jour d'actualités, une bibliothèque de ressources consultable avec plus de 1 000 publications évaluées par des pairs, et une section dédiée aux relations avec les investisseurs. Le site vise à offrir une présence en ligne unifiée pour les informations corporatives et sur les produits de l'entreprise, tout en soulignant son engagement envers la technologie de purification du sang et les thérapies salvatrices.
CytoSorbents (NASDAQ: CTSO) hat eine neu gestaltete und konsolidierte Website unter www.cytosorbents.com gestartet. Die Website mit dem Thema 'Gemeinsam Leben Retten' zeigt zwei Jahrzehnte der Zusammenarbeit mit der medizinischen und wissenschaftlichen Gemeinschaft zur Verfeinerung von Therapien wie CytoSorb®, ECOS-300CY® und VetResQ®. Die neue Seite verfügt über ein modernes Design, intuitive Navigation und umfassende Informationen für Gesundheitsfachkräfte und Investoren.
Zu den wichtigsten Funktionen gehören ein benutzerfreundliches Layout, verbesserte Inhalte, Nachrichtenupdates, eine durchsuchbare Ressourcenbibliothek mit über 1.000 peer-reviewed Publikationen und ein spezieller Bereich für die Investorenbeziehungen. Die Website zielt darauf ab, eine einheitliche Online-Präsenz für die Unternehmens- und Produktinformationen zu bieten und unterstreicht das Engagement für Blutreinigungstechnologie und lebensrettende Therapien.
- Launch of a new, comprehensive website that could improve stakeholder engagement and information dissemination
- Extensive resource library with over 1,000 peer-reviewed publications, potentially enhancing credibility and research support
- Unified online presence that may streamline marketing efforts and improve brand cohesion
- None.
“Working to Save Lives Together” Theme Highlights Two Decades of Successful Collaboration with the International Medical and Research Communities to Help Patients Survive Life-Threatening Illnesses
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com. The theme of “Working to Save Lives Together” highlights two decades of successful collaboration with the international medical and research communities to continuously refine how our therapies, such as CytoSorb®, ECOS-300CY®, and VetResQ® are being used to help patients survive life-threatening illnesses.
A Modern, Unified Online Presence
The new website, built from the ground up, unifies our corporate and product information into a single, cohesive and comprehensive information hub for healthcare professionals, investors, and other key stakeholders. Visitors will find a streamlined modern design, intuitive navigation, and extensive content on our company, technology, therapies, pipeline that includes DrugSorb™-ATR and HemoDefend-BGA™, clinical studies, investor conferences, and much more.
Key Features of the New Website:
- User-Friendly Layout and Intuitive Navigation - with easy access to essential information and optimized for both desktop and mobile browsing.
- Enhanced Easy-to-Understand Content - tailored for different stakeholders.
- News and Updates - dedicated to the latest developments and events.
- Comprehensive and Searchable Resource Library - from a collection of 1,000+ peer-reviewed publications, poster presentations, abstracts, white papers and case reports highlighting the use of our therapies in many applications.
- Introduction to Our Experts - who are there to provide guidance and support.
- Voices Around the World - with insights and feedback from users worldwide.
- Dedicated Investor Relations site - for quick access to investor materials.
- Improved Contact Forms - facilitating faster communications and interactions.
Dr. Christian Steiner, Executive Vice President of Sales and Marketing of CytoSorbents, stated, “We are grateful to all of the pioneering physicians, nurses, perfusionists, researchers, and other healthcare professionals who use our therapies in daily clinical practice or who have contributed to the many studies and the more than 1,000 references that can be found in our CytoSorb literature database on our new website. Your dedication and insights have been instrumental in shaping the success of our technology and improving patient outcomes worldwide. Likewise, as we have in the past, it is our commitment to you to be a trusted and dependable partner who will be there to support you whenever you need us.”
Dr. Steiner added, “We invite everyone to explore the new CytoSorbents website which is a celebration of all that we have accomplished together, and to learn how CytoSorbents is helping to save lives and ‘Expand the Dimension of Blood Purification™’ with our products around the world.”
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces “cytokine storm” or “cytokine release syndrome” in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. As of March 31, 2024, more than 237,000 CytoSorb devices have been used cumulatively. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved in the United States.
The DrugSorb™-ATR antithrombotic removal system, an investigational device based on the same polymer technology as CytoSorb, has received two FDA Breakthrough Device Designations, one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. The Company has completed the FDA-approved, randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 140 patients at approximately 30 centers in U.S. and Canada to evaluate whether intraoperative use of DrugSorb-ATR can reduce the perioperative risk of bleeding in patients receiving ticagrelor and undergoing cardiothoracic surgery. This pivotal study is intended to support U.S. FDA and Health Canada marketing approval for DrugSorb-ATR in this application.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, statements about potential exposures resulting from our cash positions, representations and contentions, and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 14, 2024, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
U.S. Company Contact:
Kathleen Bloch, CFO
305 College Road East
Princeton, NJ 08540
+1 (732) 398-5429
kbloch@cytosorbents.com
Investor Relations Contact:
Eric Ribner
LifeSci Advisors, LLC
250 W 55th St, #3401
New York, NY 10019
+1 (646) 751-4363
ir@cytosorbents.com
FAQ
What new products are featured on CytoSorbents' redesigned website?
How many peer-reviewed publications are available in CytoSorbents' (CTSO) new resource library?
What is the theme of CytoSorbents' (CTSO) new website launched in July 2024?
What key features does CytoSorbents' (CTSO) new website include?
